Why the study?
Do monoclonal antibodies improve clinical outcomes in patients with multiple sclerosis?
Do monoclonal antibodies improve clinical outcomes in patients with multiple sclerosis?
Monoclonal antibodies are highly effective disease-modifying therapies for multiple sclerosis, but require careful patient selection and rigorous safety monitoring.
Answers are grounded in this paper and cite their sources.
Monoclonal antibodies expand multiple sclerosis algorithms; leaves open optimal sequencing, safety, and comparative effectiveness.
Since their introduction in medical therapy, in the last quarter of the 20th century, monoclonal antibodies have gained an increasing importance in the treatment of various diseases. Neurology has been one of the medical specialties benefiting of the therapeutic potential of these monoclonal antibodies and certain neurological conditions may now contain such drugs in their therapeutic algorithms. Multiple sclerosis is one of these diseases and, in addition to the monoclonal antibodies already licensed for clinical use, several others are in development for future utilization in this specific area. The future will certainly pass through this kind of drugs and, in this article, a review of the most relevant data related to monoclonal antibodies already in use and also in clinical development for multiple sclerosis treatment will be performed.
No takes yet. Share an insight, caveat, or question.
Filipe Palavra (2015) conducted a review in Multiple Sclerosis. Monoclonal Antibodies (e.g., Natalizumab, Alemtuzumab, Daclizumab, Ocrelizumab) was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: